Latest / CME Outfitters Medical Education / Unveiling HER2-Low and Ultralow Expression in mBC: Implications for the Multidisciplinary Care Team
Transcript
- 0:03SPEAKER_00: Hello, and welcome to Reengineering the Approach to Metastatic Breast Cancer, a stepwise guide to HER2 testing and management for HER2 Low and Ultra Low Disease.
- 0:12SPEAKER_00: I'm Dr.
- 0:12SPEAKER_00: Jane Maisell, and I'm thrilled to be here with my colleagues, Dr.
- 0:15SPEAKER_00: Hatim Solomon and Dr.
- 0:17SPEAKER_00: Bill Lee, as we take a deep dive into how evolving HER2 testing and antibody drug conjugate therapies are reshaping care for patients who fall in the HER-2 low and HER2 ultra-low continuum.
- 0:28SPEAKER_00: Today's program is part one of a three-activity series created to help multidisciplinary teams navigate the evolving landscape of HER2 low and HER2 ultra-low metastatic breast cancer.
- 0:37SPEAKER_00: Over the past two decades, HER2 directed therapies have really transformed the management of breast cancer, initially benefiting only the small proportion of patients with HER2 amplification or overexpression.
- 0:47SPEAKER_00: But as we've learned that patients previously considered HER2 negative may still derive meaningful benefit from antibody drug conjugates, our traditional binary HER2 classifications have really been changed.
- 0:57SPEAKER_00: This has introduced new diagnostic and therapeutic complexities that are wonderful for patients, but impact both oncologists and pathologists in daily practice.
- 1:05SPEAKER_00: In this opening session, we'll explore how HER2 classification has evolved.
- 1:09SPEAKER_00: We'll review the most recent data supporting HER2-targeted and trope-2-targeted ADCs, and we'll discuss the pathology and reporting considerations that directly influence patient eligibility and treatment sequencing with these agents.
- 1:20SPEAKER_00: Part two will highlight real-world oncology and pathology collaboration and institutional workflow strategies.
- 1:26SPEAKER_00: Part three is we'll focus on offering a more detailed exploration of testing optimization and assay performance in HER2-low and ultra-low disease.
- 1:34SPEAKER_00: Before we dive in, I'd love for you to meet the rest of our faculty for today's program.
- 1:38SPEAKER_00: I'm joined by two outstanding colleagues who bring deep expertise across both pathology and breast oncology.
- 1:44SPEAKER_01: Thank you, Dr.
- 1:45SPEAKER_01: Mizel.
- 1:45SPEAKER_01: Yeah, my name is Dr.
- 1:46SPEAKER_01: Hatam Solomon.
- 1:47SPEAKER_01: I'm a breast medical oncologist, a senior member in the breast and immunology departments and clinical investigator at the Moffitt Cancer Center in Tampa, Florida.
- 1:56SPEAKER_01: Thank you for having me.
- 1:57SPEAKER_01: Thank you, Dr.
- 1:58SPEAKER_01: Maisel, for the unnicam.
- 2:00SPEAKER_02: I'm Billy.
- 2:01SPEAKER_02: I used to be at Emory University from 2013 until recently.
- 2:08SPEAKER_02: I moved to East Carolina University as a chair and a professor in the Department of Pathology.
- 2:14SPEAKER_00: And I'm Dr.
- 2:15SPEAKER_00: Maiselle.
- 2:15SPEAKER_00: I'm one of the breast medical oncologists here at Emory.
- 2:17SPEAKER_00: I've been here for about 10 years on faculty and currently serve as the co-director of Breast Medical Oncology.
- 2:23SPEAKER_00: Here are disclosures.
- 2:27SPEAKER_00: And here are the learning objectives for this activity.
- 2:32SPEAKER_00: So let's set the stage for the rest of today's discussion.
- 2:35SPEAKER_00: To understand where HER2 low and HER2 ultra-low fit into the broader landscape, it's helpful to look back at how HER2 directed therapies and to her HER2 classification have evolved over time.
- 2:45SPEAKER_00: So in 1998, TRESTUZAMAB became the first FDA-approved HER2 targeted therapy.
- 2:49SPEAKER_00: We had binary HER2 classification, right after TRESTUZMAB was approved, we sort of learned how best to identify patients as HER2 positive and HER2 negative.
- 2:57SPEAKER_00: And in the early 2000s, ASCO and CAP standardized their guidelines for HER2 testing methodology.
- 3:03SPEAKER_00: Things really started to accelerate in drug development in the early 20 teens when Pertuzimab and TDM1 were approved.
- 3:09SPEAKER_00: TDXD received accelerated approval later on, first for HER2 positive metastatic breast cancer after Destiny Breast O1, and then later for HER2 LOW disease after Destiny Breast O4 came along.
- 3:19SPEAKER_00: And now we're really refining what it means to be HER2 low and HER2 ultra-low as we see the results of some of these studies and see our patients start to benefit.
- 3:27SPEAKER_00: As we'll talk about over the course of the series, HER2 Ultra Low is a difficult thing to define.
- 3:31SPEAKER_00: And it's created challenges, but also opportunities for the pathologists as we start to standardize and really understand what HER2 low means and HER2 ultra-low across the board.
- 3:41SPEAKER_00: So with this evolution in mind, the next step is really understanding how we classify HER2 low and HER2 ultra-low disease in the lab.
- 3:48unknown: Dr.
- 3:48SPEAKER_00: Lee, maybe you can take us through these definitions and the key features that distinguish these categories.
- 3:53SPEAKER_02: Sure.
- 3:54SPEAKER_02: CERTUHC was defined as CR2HC0, 1, 2 plus, and 3 plus.
- 4:02SPEAKER_02: 3 plus will be HER2 positive.
- 4:04SPEAKER_02: In the old classification, IC2 plus, Fish negative, IC1 plus, and IC0 will be HER2 negative.
- 4:14SPEAKER_02: With the current development in antibody drug conjugate, HER2 low is currently defined as IC2 plus, H negative, and IC1 plus, those will be classified as HER2 low.
- 4:28SPEAKER_02: HER2 ultra low is currently defined as HER2HC0, but with some membrane staining, with fan incomplete membrane staining in less than 10% of tumor cells.
- 4:43SPEAKER_00: So building on these definitions, let's examine the clinical evidence behind this shift.
- 4:47SPEAKER_00: Dr.
- 4:47SPEAKER_00: Solomon, maybe you could walk us through some of these ADCs and the trials that led to their approvals.
- 4:52SPEAKER_01: Sure, be happy to.
- 4:54SPEAKER_01: So in general, antibody drug conjugates or ADCs is referred to transformed the landscape for metastatic breast cancer.
- 5:01SPEAKER_01: And it looks like it may be making an impact potentially even in the earlier curative stage.
- 5:05SPEAKER_01: And the way to think about these is it offers a targeted cytotoxic delivery vehicle that can have an impact across multiple molecular subtypes of breast cancer.
- 5:16SPEAKER_01: And uh three of the drugs that have been recently developed and are approved are sazituzimab govitican, which is an antibody that targets the trope two.
- 5:27SPEAKER_01: And then you have uh datapodamab druxatecan.
- 5:30SPEAKER_01: And uh that is uh basically another trope two targeting IgG1 antibody, and then uh you have TRESTUZIMAB DRUXITAN, which is a HER2-targeting IgG1 antibody.
- 5:42SPEAKER_01: And so here you can see between uh all these antibodies, at least we have a variety of means to target the cells to try to deliver these topaisomerase 1 payloads in order to exert their therapeutic effect.
- 5:54SPEAKER_01: So now uh we'll go into the first trial that established the efficacy of tristusomab drug cetican in her two low uh breast cancer.
- 6:03SPEAKER_01: Um and this is uh the Destiny Breast O4 uh trial which uh looked at patients with IHC1 plus or two plus disease uh that had to be ish negative and uh they were metastatic or uh locally advanced unresectable and have been treated with one to two prior lines of therapy in the metastatic setting.
- 6:24SPEAKER_01: And they were randomized two to one to either get uh TDXD at the typical schedule at 5.4 milligrams per kilogram over three weeks versus basically dealer's choice chemo.
- 6:34SPEAKER_01: And the primary endpoints was progression free survival.
- 6:37SPEAKER_01: And here you can see the efficacy data is very convincingly and clearly favoring the use of TDXD over standard chemotherapy with a hazard ratio reduction of 0.36, showing that basically the risk of progression was dramatically reduced in patients who were treated with TXD.
- 6:57SPEAKER_01: And the median progression free survival was 8.8 months versus 4.2 months median in the chemotherapy group and this separation in the curves happened early and was sustained throughout the entire period of treatment.
- 7:11SPEAKER_01: And notably in the hormone receptor negative cohort the median progression free survival specifically was 6.3 months versus 2.9 months with a hazard ratio of 0.29 again showing that the drug is highly active in both hormone receptor positive and triple negative breast cancer that is her too low.
- 7:31SPEAKER_01: And looking at overall survival again uh this was um highly significant and looking at uh the difference here uh is clinically meaningful with the curve separating quite early on in follow-up with a TDXD showing uh an overall survival uh at median at 22.9 months versus 16.8 months with chemotherapy the hazard ratio is 0.69 and the hormone receptor negative cohort uh the median overall survival was 17.1 months versus 8.3 months for standard chemotherapy with a hazard ratio of 0.58 um and uh again showing that there appeared to be clinically meaningful differences in overall survival uh with the use of TDXD uh in this um uh setting for the patients that have IHC1 disease or IHC two disease, the efficacy of the drug was similar in these categories, showing a median progression free survival of around 10 months for both categories of IHC scoring with similar reductions in hazard ratio.
- 8:35SPEAKER_01: But this at least reassures us that patients will derive significant benefit from TDXD irrespective of whether they're IHC one plus or two plus perfect that was such a great review.
- 8:49SPEAKER_00: Given how transformative Destiny Breast O4 has been over the time since it was first presented I think this is a good point to step back and talk through what it means for each of us clinically.
- 8:57SPEAKER_00: When you saw the results of this trial and started thinking about this as an option for patients did you start reevaluating or retesting archived tissue from prior biopsies to identify her to low patients or how did you go about thinking about that topic?
- 9:10SPEAKER_01: Yeah we we would work closely with our our pathology colleagues in general to try to identify prior testing and reports that had been done on patients.
- 9:18SPEAKER_01: But there were cases where we didn't have the information or it was HER2 null or zero in an older prior specimen.
- 9:27SPEAKER_01: So sometimes we would retest a different sample or recheck it at our center to see if that truly was a null or if it was her too low in our hands.
- 9:36SPEAKER_01: And often we would find patients additionally to treat with tristus Tant uh following the retesting.
- 9:44SPEAKER_00: So I agree if I had someone who had a historical IHC of one plus or two plus, I really didn't look any further.
- 9:50SPEAKER_00: I just sort of reclassified them in my as in my notes as HER2 low as opposed to HER2 negative and then moved on knowing that when they progressed they would be a candidate for TDXD.
- 9:59SPEAKER_00: But there were some patients that I have gone back to look at prior specimens or even in patients who were HER2 zero biopsied something new at progression to try to understand whether they might be a HER2 low patient and therefore a TDXD candidate now.
- 10:14SPEAKER_01: How do you go about uh figuring out that question of when when to potentially repeat a biopsy versus not well I think you know there's a few different factors and Bill maybe also to kind of um you know clarify this is you know sometimes we've got samples for example that have very scant cellularity or they may have been like bone biopsies that had a minimal amount of tissue and may have gone through some additional processing or decalcification, in which case that could alter the intensity of the staining for some of these markers.
- 10:41SPEAKER_01: And you may be working off of equivocal or borderline results that even the the pathologist who was doing the interpretation would comment on.
- 10:50SPEAKER_01: So those are cases that we'd prioritize to try to get new testing or or another biopsy.
- 11:06SPEAKER_02: I completely agree with you that when we find that the cellularity of the old specimen is too low or of all the specimens from metastatic to biopsy to surgical we are really trying to test all the specimens to give the patient to make the patient eligible for this HER2 topic therapy but if the tissue is has a lot of necrosis tissue cellularity is low that can the the retesting does not really reflect the biology of tumor then we will recommend a repeat biopsy.
- 11:47SPEAKER_00: Perfect and then what about discordance?
- 11:50SPEAKER_01: Yeah if you've got a primary cancer that is maybe HER2 zero and a metastatic specimen that's HER2 low, then I think you you know in terms of treatment we're usually going off of that metastatic specimen and treating the HER2 low patient uh treat them as HER2 low in the metastatic setting if your um initial specimen had been HER2 low and now you had a metastatic uh recurrence where the patient was HER2 zero um would you retest and when would you retest um if if you would I I would say I'd be a little provocative about the the discussion is that in general if I have any result that has HER2 low expression uh you know in the primary or metastatic in my mind I feel that that's uh justification for uh potentially exposing the patient to the drug uh simply because there's a lot of heterogeneity in HER2 expression particularly across disease um locations within the same patient um and also the difference between live tissue and fixed tissue even uh you can have a difference in in HER2 expression.
- 12:57SPEAKER_01: And so I feel that if I have a positive HER2 low result from either the primary or metastatic, I feel that I would I would feel comfortable trying to give the patient a chance on trystusimab diroxatecan whereas if the only result I had was a uh a null primary and a metastatic that hadn't been tested, then in many cases I will try the repeat test in order to try to get them access to tristusimab diroxy Tcan because it's such an effective drug.
- 13:28SPEAKER_01: I feel that I'm gonna go out of my way to try to give my patients those opportunities to benefit from it.
- 13:34SPEAKER_00: Absolutely I actually don't disagree at all.
- 13:36SPEAKER_00: I think um for me it's really about getting access to the agent and if I can check a box that they've been hurt too low at any point, I will check that box because I do feel like it's worth worth trying.
- 13:47SPEAKER_00: Many of these patients as we see in the clinic, if they're going to respond, we'll respond quickly.
- 13:51SPEAKER_00: So it's not like you're gonna have them exposed to a drug for many, many months where it might not be working.
- 13:55SPEAKER_00: I think you're gonna know one way or the other.
- 13:57SPEAKER_00: Well thank you both for a great discussion.
- 13:59SPEAKER_00: I think as the field absorbed the impact of Destiny Breast O4, the natural next step was to ask of course whether the same benefit might be seen earlier in metastatic disease and whether it might extend into the ultra low category.
- 14:11SPEAKER_00: How much HER2 expression do you actually need for this drug to benefit you?
- 14:15SPEAKER_00: And that was exactly what Destiny Breast O6 really set out to explore.
- 14:19SPEAKER_00: It was HER2 low patients or HER2 ultra low, the IHC0 with some membrane staining these patients had to have received at least two lines of endocrine therapy or one line of endocrine therapy in the metastatic setting and then progression after starting it six months later or not.
- 14:34SPEAKER_00: But then these patients had not received chemo yet that was really the key criterion and they were randomized to either TDXD or treatment of physicians choice chemotherapy.
- 14:43SPEAKER_00: Primary endpoint was progression free survival and then you can see the key secondary endpoints here.
- 14:48SPEAKER_00: So when you look at the outcomes um this was very impressive so we had 430 roughly patients in each arm and you can see the very clear separation of curves with progression free survival of 13.2 months in the TDXD arm versus 8.1 months in the patients who received treatment of physicians choice chemotherapy and this was really the same in the HER2 low and also the HER2 ultra low cohort.
- 15:10SPEAKER_00: So really showing that patients benefited both earlier before getting any chemo in the metastatic setting and also benefited if there were HER2 low or HER2 ultra low.
- 15:18SPEAKER_00: So opened up this opportunity potentially for patients in a slightly new category that HER2 ultra low category.
- 15:24SPEAKER_00: So in January of this year, really hot off the presses the FDA approved TDXD for unresectable or metastatic hormone positive HER2 low or HER2 ultra low breast cancer.
- 15:34SPEAKER_00: I think the important thing to note about this study all the patients in Destiny breast 06 were hormone positive.
- 15:39SPEAKER_00: So we don't technically know how the drug performs in a hormone negative HER2 ultra low patient, but this is sort of where the data is today.
- 15:46SPEAKER_00: I guess then the next corollary question to that is does true HER2 zero breast cancer really exist?
- 15:52SPEAKER_00: Or do we think current assays are just failing to detect ultra-low expression that may still respond to TDXD?
- 15:57SPEAKER_00: Bill, I'd be particularly interested in your input on that question.
- 16:01SPEAKER_02: That's really a good question.
- 16:03SPEAKER_02: I think every tumor expressed some kind of HER2 protein the original assay was designed to to detect HER2 positive breast cancer and it was not the designed to differentiate low HER2 expression level so um do true whether it's true HER2 zero breast cancer really exists that means HER2 tumor has no HER2 protein at all I don't think um we have enough evidence yet um but from the original study and laboratory study all the HER2 uh all the breast cancer have some kind of HER2 protein expression it's just our current essay is not designed to detect and differentiate HER2 protein expression at very low level Dr.
- 17:05SPEAKER_01: Salman any additional comments on that yeah no I agree and I think also uh just to reiterate that um some of our assays and and there's been efforts over the years to try to develop different tools to try to detect um additionally like lower levels of HER2 uh that weren't captured by a lot of our standard assays um those never really I think uh reached widespread adoption because again the clinical relevance wasn't as clear for predicting response to typical anti-HER2 agents.
- 17:39SPEAKER_01: But you may see more interest now in some of these assays coming back to try to further define HER2 low and ultra low patients using more sensitive assays you know that are better calibrated to that lower end of the spectrum of HER2 expression.
- 17:56SPEAKER_01: So I think uh we may see newer diagnostics uh come to to fill in that uh unmet need.
- 18:03SPEAKER_00: Yeah, absolutely.
- 18:04SPEAKER_00: So now as we think about treatment sequencing for patients with HER2 low and ultra low disease, we need to look beyond HER2 targeted ATCs.
- 18:11SPEAKER_00: So let's shift now to the role of trope two directed antibody drug conjugates and how those fit into the broader metastatic breast cancer landscape.
- 18:18unknown: Dr.
- 18:18SPEAKER_00: Solomon I was hoping you might be able to walk us through some of this data.
- 18:22SPEAKER_01: Sure thing so pivotal trope two trials were designed in those patients that we traditionally called HER2 negative that could have been ultra low one plus two plus we didn't stratify them differently in those trials.
- 18:34SPEAKER_01: Now despite this trope 2 antibody drug conjugates they are commonly used in patients with HER2 low and ultra-low metastatic breast cancer particularly after progression on endocrine therapies, chemotherapy lines or even used in sequence after HER2 targeting antibody drug conjugates like TDXD.
- 18:51SPEAKER_01: So the first study Tropic CO2 was looking at the efficacy of sazetozimabobiticin and pre-treated hormone receptor positive HER2 negative breast cancer that's metastatic.
- 19:02SPEAKER_01: These patients uh would have had at least one endocrine linotherapy um and often combined with CDK46 and then also saw uh chemotherapy with a prior taxane they would have at least uh two but no more than four lines of chemo in the metastatic setting and they could have been HER2 zero, one plus or two plus ish negative and they have measurable disease.
- 19:23SPEAKER_01: And they were randomized one to one to get sazituzamab gobotican and typical schedule 10 milligrams per kilogram days one and eight every three weeks versus dealer's choice chemo.
- 19:33SPEAKER_01: Primary endpoint was progression free survival for the trial.
- 19:38SPEAKER_01: Here I could see a significant increase in the progression free survival median at 5.5 versatuzomagobotican compared to four months in the chemotherapy alone arm the hazard ratio 0.65 and the p-value is highly statistically significant.
- 19:54SPEAKER_01: This also was accompanied with an overall survival uh difference was observed a median about 14 and a half months in sazatusomabotican versus around 11 months for standard chemo.
- 20:05SPEAKER_01: Again highlighting the clinical benefit of the agent in this uh pre-treated setting so then we'll move on to uh the other trope two targeting antibody uh the cyanotropian breast01 using data potomab dioxidecan versus chemotherapy in a similar population so these patients uh would have seen prior endocrine lines of therapy uh they had one to two prior lines of chemo so they were pre-treated albeit they uh may have been a little less heavily treated uh than TropicSO2 and they were randomized one to one to get uh data potomab diroxytican which is given once every three weeks at six milligrams per kilogram uh versus uh the the again selection of standard chemo and uh they had a dual primary endpoint of progression free survival uh and overall survival um as as uh the study was designed to show both and um here you can see at least in uh the median progression free survival uh datapodomab druxetic and outperformed standard chemo with a median uh pfs of 6.9 months versus 4.9 for the standard chemo again the curve separated early and stayed separated throughout has a ratio 0.63 now there was a trend towards improved overall survival uh but this uh was not statistically significant uh the confidence intervals uh crossed one and uh one thing though to note though is that at the time of the reporting the overall survival data is still immature and events are still occurring and need to be followed over time.
- 21:36SPEAKER_01: Now if you're looking at uh using uh uh data podamap druxetican and the uh tropion breast O2 trial uh in this case now you had metastatic triple negative breast cancers compared to hormone receptor positive breast cancer and these patients were not treated in the metastatic setting previously so uh and they were um allowed to have um uh a Ecoch performance status is zero to one.
- 22:03SPEAKER_01: And there was no minimum disease-free interval mandated for eligibility for this trial.
- 22:08SPEAKER_01: Patients were randomized one to one to data podemab, again, same schedule and dose versus similar chemotherapies as well, with a dual primary endpoint again of overall survival and progression-free survival.
- 22:21SPEAKER_01: And here what you can see is that in uh the first line metastatic uh triple negative breast cancer setting, uh datapodomab direxa TCAN significantly outperformed standard chemotherapy again with a hazard ratio of 0.57.
- 22:35SPEAKER_01: The median PFS was 10.8 months in the data arm versus 5.6 in the control.
- 22:41SPEAKER_01: Um, so and if you look at the the overall survival, there again was a trend towards improved survival.
- 22:48SPEAKER_01: So the median was around 23.7 months uh versus 18.7 in the control.
- 22:53SPEAKER_01: The delta for both of these comparisons was right around five months.
- 22:57SPEAKER_01: Uh, and so again, uh a highly statistically significant difference in PFS with an early trend towards improved OS, suggesting that data podamab may be an attractive option for some of our metastatic triple negative breast cancer patients who are not eligible for uh immunotherapy or for um uh potentially getting sacetousimab, gobatican in the first line as well.
- 23:20SPEAKER_00: Absolutely.
- 23:21SPEAKER_00: And I think with the turbambesto 2 data in mind, this is a good point for us to step back and think about how we're sequencing these ADCs in real world practice.
- 23:28SPEAKER_00: Now, you know, currently in the metastatic HR-positive HER2 low setting, we have three available ADCs, TDXD, Sasatuzimab, and DATO.
- 23:37SPEAKER_00: And what factors are kind of characterizing for you, Dr.
- 23:40SPEAKER_00: Solomon, how you're sequencing these and thinking about uh using these in patients who qualify for all three, those HER2 low and HER2 ultra-low patients?
- 23:48SPEAKER_01: Yeah, it's a critical question.
- 23:50SPEAKER_01: And I have a philosophy of always trying to put my best foot forward, if you will, in terms of prioritizing my agents, you know, to maximize benefit because there is some pretty clear data that's been emerging repeatedly that there may be some cross-resistance going from the first antibody to the second antibody due to potentially similarity in the payloads as far as the mechanism of action.
- 24:10SPEAKER_01: So we're always trying to look for well, what gave us the biggest bang for our buck and where's the data most solid for using that ADC in that particular line?
- 24:18SPEAKER_01: And I tend to favor for my hormone receptor positive um HER2 low patients.
- 24:23SPEAKER_01: I think the strength of the TDXD data is pretty um powerful.
- 24:27SPEAKER_01: And I would tend to prioritize using it as early as possible over, say, Sazatuzimab Govitacan or DADO.
- 24:37SPEAKER_01: Um and then I feel that in the triple negative setting, at least historically, with the ascent uh trials data, Sazatuzimab Govitacan had a much larger dedicated TNBC population, if you will, that had shown efficacy and survival data.
- 24:53SPEAKER_01: Um, whereas, as you alluded to before, for 04, there was a very small number of triple negative breast cancers that were HER2 low treated on that trial.
- 25:01SPEAKER_01: So, you know, the idea is that we kind of prioritize SAZITUM GOVITCAN for our triple negative patients, uh, more often than not, with TDXD being used in those HER2 lows that are triple negative as a potential second option.
- 25:14SPEAKER_01: And so I think uh now data podamab, druxatecan, uh, we're trying to look and see like, well, where does this agent fit in uh with those other data sets?
- 25:23SPEAKER_01: And that's been something that there's been a lot of discussion about right now, uh, with especially the um uh tropian O2 data that's come out.
- 25:31SPEAKER_01: Um, how would we pick these patients for say upfront SASITUSAMAP versus uh data podamab?
- 25:38SPEAKER_01: For some of the main issues now that we're looking at, uh, Dr.
- 25:41SPEAKER_01: Mizel's like the different payload containing antibody drug conjugates, I think will also expand our armamentarium.
- 25:48SPEAKER_01: So as we pointed out, all the antibodies we discussed had uh uh tobisomerase one inhibitor uh targeting payloads, whereas now we're having uh, you know, other antibodies like uh dise Mabidotin and um and MRGOO2, like others that can have a different mix of targets and payloads that may allow us to treat serially using antibody drug conjugates with different payloads against different targets to maintain efficacy over time.
- 26:15SPEAKER_00: Yeah, absolutely.
- 26:16SPEAKER_00: And I do think some of that, you know, well, answers will come in time.
- 26:19SPEAKER_00: But I think one of the interesting questions will be you know, all of us, if you use enough TDXD, you're gonna see pneumonitis as a potential toxicity.
- 26:27SPEAKER_00: Um we certainly see a lot less pneumonitis, if any, with uh DATO and SASI.
- 26:31SPEAKER_00: Um, and it did make me kind of wonder as we sort of see some of this data for data podam come out.
- 26:36SPEAKER_00: Um, obviously the payload is very, very similar between TDXD and DATO DXD.
- 26:41SPEAKER_00: Um, but could you potentially use DATO and someone who's developed pneumonitis on TDXD?
- 26:45SPEAKER_00: I don't know.
- 26:46SPEAKER_00: Um, so I think there are a lot of unanswered questions that potentially, you know, real-world data or eventual trials may help us with.
- 26:52SPEAKER_00: Um, but I agree with your general philosophy of sort of TDXD for those hormone-positive HR low patients, um kind of prioritizing SASI and maybe now bringing data into the mix for metastatic uh triple negative patients, particularly those who are uh PDL1 negative.
- 27:07SPEAKER_00: Um, I think you know, applying these therapies and practices, as I alluded to, talking a little bit about toxicity there, is not just about efficacy.
- 27:13SPEAKER_00: It also requires a strong understanding of the safety profiles of each of these drugs and how to manage toxicities effectively.
- 27:19SPEAKER_00: So we'll talk a little bit about some of the common adverse events we see with ADCs and some of the strategies that we use across these trials.
- 27:26SPEAKER_00: So with TDXD, as we talked about, interstitial lung disease is probably the main uh adverse event of interest.
- 27:32SPEAKER_00: Across all studies, we pretty much see this in about 10% of patients.
- 27:35SPEAKER_00: So, as I said, if you use enough TDXD, you will see this.
- 27:38SPEAKER_00: Um, more common, but a little less uh sort of frightening is nausea, vomiting, and fatigue.
- 27:44SPEAKER_00: I will say some of the things that I've found effective are three days of morning dexamethasone and nighttime melanzepine to help with energy during the day, um, sleep at night, and then to manage that nausea and vomiting.
- 27:55SPEAKER_00: And then as far as ILD, making sure patients are aware of this potential risk, making sure that you're monitoring them closely, both clinically and with imaging, and making sure that if you see ILD, either grade one on a scan or grade two or higher clinically, that you're interrupting and potentially thinking about steroids right away.
- 28:12SPEAKER_00: And then one of the things that I've done also is sometimes if I have a patient who's a little frailer and I might be more worried about toxicities, I might start them at 4.4 milligrams per kilogram instead of the 5.4 starting dose and then escalate if they tolerate the drug well.
- 28:24SPEAKER_00: And then with SASI, we mostly are seeing neutropenia and diarrhea.
- 28:28SPEAKER_00: Um use of GCSF is, of course, very helpful.
- 28:31SPEAKER_00: Some patients, um, if you need to, you can go to day one, day 15 dosing as opposed to day one, day eight, so that you can use long-acting growth factor.
- 28:38SPEAKER_00: And then just encouraging patients to make sure that they have laperamide on hand, that they know that we can prescribe additional antidiarrheals if needed and to maintain hydration.
- 28:46SPEAKER_00: I've had some patients who've needed IV fluids along with treatment to kind of stay up on the diarrhea, but those are some of the main things that we do.
- 28:52SPEAKER_00: And then some of the unique side effects of uh dato include moral mucositis and stomatitis, and then also ocular toxicity.
- 29:00SPEAKER_00: So often we are using eye drops prophylactically and during treatment for mucositis.
- 29:04SPEAKER_00: I have patients often suck on an ice pop during the infusion, um kind of like a cold cap.
- 29:08SPEAKER_00: That's helpful for protecting uh the oral mucosa.
- 29:11SPEAKER_00: And then we use a steroid mouthwash, often like we do with Everolimus, um, to help with this drug as well.
- 29:16SPEAKER_00: And then you know, we see less ILD with data than we do with TDXD, as I mentioned, um, but important to be vigilant.
- 29:23SPEAKER_00: So, you know, I think you know how we use these ADCs and how we sequence them all really hinges on how we're assessing HER2 in the lab.
- 29:29SPEAKER_00: So, Bill, as we think uh towards wrapping up, I want to see if you could maybe walk us through current testing and reporting considerations.
- 29:37SPEAKER_02: Sure.
- 29:37SPEAKER_02: Thank you.
- 29:38SPEAKER_02: Um, with the ADC coming along the way, uh, that also changed our practice in pathology.
- 29:47SPEAKER_02: Um, as we know, HER2 past breast cancer accounts for about 15% of all the breast cancers.
- 29:53SPEAKER_02: Now the CER2 low, which is one plus and two plus each inactive, counts about uh 50 to 55% of all the breast cancer, HER2 ultra-low, which is HER2 IC0, but with some membrane standing account for about 10% of all breast cancer, HER2 null type, which is HER2 zero, with no uh tumor cell standing for HER2 antibody, account for about 10 to 20 percent of all the breast cancer.
- 30:23SPEAKER_02: Um the 2023 ISCO CEP guidelines uh pretty much did not change from the 2018 recommendations.
- 30:34SPEAKER_02: There's no change in the scoring system for HER2 um evaluation.
- 30:40SPEAKER_02: However, because of the current practice change, using antibody drug conjugate is critical for pathologists to separate um HER2 null type, HER2 ultralow, and HER2 low subtype uh uh HC staining.
- 31:00SPEAKER_02: Um it's recommended by the ASCO CAP guidelines that pathologists need to use high power, which is 40x, to really evaluate tumors with low HER2 expression, and also recommended pathology report to include HER2 ultra-low, HER2 low uh status.
- 31:24SPEAKER_02: Um, so that's some current changing in the pathology world.
- 31:29SPEAKER_00: Perfect.
- 31:30SPEAKER_00: No, I think it's a really exciting area with a lot of change, which is great for patients.
- 31:34SPEAKER_00: And I think now that we have more precise testing, we're integrating antibody drug conjugates earlier and earlier, and as new drugs coming to market, um, we'll be able to continue to redefine this HER2 negative and HER2 low landscape and personalize therapy even better for our patients.
- 31:50SPEAKER_00: So thank you all for being here today, and thank you both for joining me on the panel.
- 31:53SPEAKER_00: It's clear that the intersection of evolving therapeutics and precise pathology will continue to reshape how we care for these patients.
- 31:59SPEAKER_00: And we hope this session has provided a practical, multidisciplinary framework that all of you can bring back to your teams at home.
- 32:05SPEAKER_00: Thank you for joining us, and we look forward to seeing you in the other activities within this series.